Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer
- 590 Downloads
Erratum to: Invest New Drugs
The original version of this article unfortunately contains some errors in the text describing the incidences of toxicities. The correct text is given below:
All 109 patients who received the initial combination therapy were assessable for safety analysis. The major adverse events for each treatment period (entire, initial combination, and maintenance periods) are shown in Table 3. Hematologic toxicities reaching ≥ grade 3 were neutropenia (56.9 %), thrombocytopenia (41.3 %), anemia (31.2 %), and leukopenia (22.0 %). Nonhematologic toxicities observed in more than half of patients included appetite loss (75.2 %), nausea (74.3 %), fatigue (67.9 %), and ALT increased (51.4 %), but the incidence of toxicities of grade 3 or higher was less than 10 %. The majority of adverse events were observed during the initial 4 cycles of pemetrexed and carboplatin combination therapy. Common toxicities ≥ grade 3 observed in the maintenance period were similar to those observed during the initial combination treatment period, including neutropenia (40.0 %), thrombocytopenia (16.7 %), leukopenia (11.7 %), and anemia (13.3 %). Newly emerged or deteriorated toxicities during maintenance periods were rarely observed. No treatment-related deaths were reported in this study.